Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P78357
UPID:
CNTP1_HUMAN
Alternative names:
Neurexin IV; Neurexin-4; p190
Alternative UPACC:
P78357
Background:
Contactin-associated protein 1, known alternatively as Neurexin IV, Neurexin-4, or p190, plays a pivotal role in the nervous system. It is essential, alongside CNTNAP2, for the radial and longitudinal organization of myelinated axons, contributing to the formation of distinct domains crucial for nerve impulse conduction in myelinated nerve fibers. This protein demarcates the paranodal region of the axo-glial junction and, in association with contactin, facilitates signaling between axons and myelinating glial cells.
Therapeutic significance:
Contactin-associated protein 1 is linked to severe neurological disorders, including Lethal congenital contracture syndrome 7 and Congenital hypomyelinating neuropathy 3. These conditions underscore the protein's critical role in neuromuscular development and function. Understanding the role of Contactin-associated protein 1 could open doors to potential therapeutic strategies for these debilitating diseases.